Ivermectin converts cold tumors hot and synergizes with immune checkpoint blockade for treatment of breast cancer (2021)

Peer-Reviewed Study · Draganov D; Han Z; Rana A; Bennett N; Irvine DJ; Lee PP · March 2, 2021

Draganov D et al., 2021-03-02: Mouse 4T1 breast cancer study reporting that ivermectin induces immunogenic cell death and T-cell infiltration, reduces immunosuppressive myeloid cells and Tregs, and synergises with anti-PD1 to shrink tumours, prevent relapse and cure metastatic disease.

While neither agent alone showed efficacy in vivo, combination therapy with ivermectin and checkpoint inhibitor anti-PD1 antibody achieved synergy in limiting tumor growth (p = 0.03) and promoted complete responses (p < 0.01), also leading to immunity against contralateral re-challenge with demonstrated anti-tumor immune responses.

n/a (HTML full text)

Draganov D et al., 2021-03-02: Mouse 4T1 breast cancer study reporting that ivermectin induces immunogenic cell death and T-cell infiltration, reduces immunosuppressive myeloid cells and Tregs, and synergises with anti-PD1 to shrink tumours, prevent relapse and cure metastatic disease. Study type: mouse 4T1 breast cancer models (neoadjuvant, adjuvant, metastatic, re-challenge). N: not stated in the abstract. Country: USA (City of Hope, Duarte CA; MIT Koch Institute). Dose: ivermectin 5 mg/kg oral gavage daily for 6 days; anti-PD1 10 mg/kg subcutaneously weekly; comparator: no treatment, each single agent. Funder: NIH P30 CA033572. Declared COI: 'The authors declare no competing interests.' CRITICAL STATUS UPDATE: this paper carries a 2026 Editorial Expression of Concern (IVC-42) and a 2026 Author Correction (IVC-43) over duplicated figure panels. Also filed as IVA-13 (claims C3, C7). Study type: animal.